Share This Article:

Sensitivity Evaluation of Two Human Breast Cancer Cell Lines to Tamoxifen through Apoptosis Induction

Abstract Full-Text HTML XML Download Download as PDF (Size:2920KB) PP. 70-77
DOI: 10.4236/ojapo.2014.34008    3,642 Downloads   4,639 Views   Citations

ABSTRACT

Tamoxifen citrate (TAM) has been used to treat breast cancer in women for many years. The com-parative effects of TAM in inducing apoptosis were evaluated in estrogen receptor-positive (ER- positive MCF-7) and estrogen receptor-negative (ER-negative MDA-MB-231) human breast cancer cell lines in vitro in order to determine if these two cell lines differ in their sensitivity to TAM. Mi-tochondrial membrane permeability potential disruption was assessed in both cell lines by a lip-ophilic cationic dye (DePsipher assay, Trevigen, Inc.) utilizing fluorescence microscopy. Using this specific fluorochrome, we were able to associate mitochondrial membrane disruption to early, mid-, and late apoptotic cells. TAM induced cell death via apoptosis in both ER-positive and ER- negative cells, however, apoptosis induction was more pronounced in ER-positive MCF-7 compared to ER-negative MDA-MB-231 breast cancer cells. These findings may have some therapeutic use in the treatment of estrogen dependent and estrogen independent breast cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Keene, S. , Azuelos, C. and Majumdar, S. (2014) Sensitivity Evaluation of Two Human Breast Cancer Cell Lines to Tamoxifen through Apoptosis Induction. Open Journal of Apoptosis, 3, 70-77. doi: 10.4236/ojapo.2014.34008.

References

[1] National Cancer Institute at the National Institute of Health (2014)
http://www.cancer.gov/cancertopics/types/breast
[2] U.S. Food and Drug Administration: Center for Drug Evaluation and Research (1977) FDA Oncology Tools Approval Summary for Tamoxifen.
http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=61
[3] Friedman, M.A. (1998) Tamoxifen. Statement of Lead Deputy Commissioner, FDA, US Department of Health and Human Services before Congressional Caucus for Women’s Issues.
http://www.fda.gov/NewsEvents/Testimony/ucm115118.htm.
[4] Wozniak, K., Kolacinska, A., Blasinka-Morawiek, M., Morawiek-Bajda, A., et al. (2007) The DNA-Damaging Potential of Tamoxifen in Breast Cancer and Normal Cells. Archives of Toxicology, 81, 519-527. http://dx.doi.org/10.1007/s00204-007-0188-3
[5] MacGregor, J.I. and Jordan, V.C. (1998) Basic Guide to the Mechanisms of Antiestrogen Action. Pharmacology Review, 50, 151-196.
[6] Obrero, M., Yu, D. and Shapiro, D. (2002) Estrogen Receptor-Dependent and Estrogen Receptor-Independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-Induced Programmed Cell Death. Joural of Biological Chemistry, 277, 45695-45703. http://dx.doi.org/10.1074/jbc.M208092200
[7] Jordan, V.C. (1998) Designer Estrogens. Scientific American, 297, 60-67.
http://dx.doi.org/10.1038/scientificamerican1098-60
[8] Renoir, J.M., Bouclier, C., Seguin, A., Marsad, V. and Sola, B. (2008) Antioestrogen-Mediated Cell Cycle Arrest and Apoptosis Induction in Breast Cancer and Multiple Myeloma Cells. Journal of Molecular Endocrinology, 40, 101-112. http://dx.doi.org/10.1677/JME-07-0143
[9] Goetz, M., Schaid, D., Wickerham, D., Safgren, S., Mushiroda, T., Kubo, M., Batzler, A., Costantino, J., Vogel, V.G., Paik, S., Carlson, E., Flockhart, D., Wolmark, N., Nakamura, Y., Weinshilboum, R., Ingle, J. and Ames, M. (2012) Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P-1 and P-2 Clinical Trials. Clinical Cancer Research, 17, 6944-6951. http://dx.doi.org/10.1158/1078-0432.CCR-11-0860
[10] Mandlekar, S., Yu, R. and Tan, T.H. (2000) Activation of Caspase-3 and c-Jun NH2-Terminal Kinase-1 Signaling Pathways in Tamoxifen-Induced Apoptosis of Human breast Cancer Cells. Cancer Research, 60, 5995-6000.
[11] Mandlekar, S. and Kong, A.N.T. (2001) Mechanisms of Tamoxifen-Induced Apoptosis. Apoptosis, 6, 469-477. http://dx.doi.org/10.1023/A:1012437607881
[12] Salami, S. and Karami-Tehrani, F. (2003) Biochemical Studies of the Apoptosis Induced by Tamoxifen in Estrogen Receptor Positive and Negative Breast Cancer Cell Lines. Clinical Biochemistry, 36, 247-253. http://dx.doi.org/10.1016/S0009-9120(03)00007-9
[13] McFadden, P. and Majumdar, S.K. (2012) Differential Sensitivity Evaluation of MCF-7 and MDA-MB-231 Human Breast Cancer Cells Exposed to Tamoxifen Alone and in Combination with Estradiol. International Journal Pharma and Bio-Science, 3, 541-548.
[14] Perry, R., Kang, Y. and Greaves, B. (1995) Effects of Tamoxifen on Growth and Apoptosis of Estrogen-Dependent and -Independent Human Breast Cancer Cells. Annals of Surgical Oncology, 2, 238-245. http://dx.doi.org/10.1007/BF02307030
[15] Majumdar, S.K., Valdellon, J.A. and Brown, K.A. (2001) In Vitro Investigations on the Toxicity and Cell Death Induced by Tamoxifen on Two Non-Breast Cancer Cell Types. Journal of Biomedicine and Biotechnology, 1, 99-107. http://dx.doi.org/10.1155/S1110724301000316
[16] Hasan, N., Kurt, R. and Majumdar, S.K. (2012) Investigation of the Roles of ATM and ATR in Tamoxifen-Induced Apoptosis in 4T1 Mouse Breast Cancer Cells. International Journal of Life Science and Pharma Research, 2, 304-320.
[17] Deal, C. and Draper, M. (2006) Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis: A Clinical Update on Efficacy and Safety. Women’s Health, 2, 199-210.
http://dx.doi.org/10.2217/17455057.2.2.199
[18] Habel, L.A., Pressman, A., Ettinger, B., Sidney, S., Suh-Burgmann, B., Fehrenbacher, L. and Quesenberry, C.P. (2006) Use of Raloxifene among Women with a History of Breast Cancer. Breast Cancer Research and Treatment, 96, 123- 129. http://dx.doi.org/10.1007/s10549-005-9069-8
[19] Vogel, V.G. (2009) The NSABP Study of Tamoxifen and Raloxifene (STAR) Trial. Expert Review of Anticancer Therapy, 9, 51-60. http://dx.doi.org/10.1586/14737140.9.1.51
[20] Baum, M., Budzar, A.U., Cuzick, J., Forbes, J., Houghton, J.H., Klijn, J.G. and Sahmoud, T. (2002) Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: First Results of the ATAC Randomised Trial. The Lancet, 359, 2131-2139. http://dx.doi.org/10.1016/S0140-6736(02)09088-8
[21] Xanthopoulos, J.M., Romano, A.E. and Majumdar, S.K. (2005) Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen and the Combination. Journal of Biomedicine Biotechnology, 1, 10-19.
http://dx.doi.org/10.1155/JBB.2005.10
[22] Thompson, E.W., Reich, R., Shima, T.B., Albini, A., Graf, J., Martin, G.R., Dickson, R.B. and Lippman, M.E. (1988) Differential Regulation of Growth and Invasiveness of MCF-7 Breast Cancer Cells by Antiestrogens. Cancer Research, 48, 6764-6768.
[23] Zamzami, N., Marchetti, P., Castedo, M., Hirsh, T., Susin, S.A., Masse, B. and Kroemer, G. (1996) Inhibitors of Permeability Transition Interfere with the Disruption of the Mitochondrial Transmembrane Potential during Apoptosis. FEBS Letters, 384, 53-57. http://dx.doi.org/10.1016/0014-5793(96)00280-3
[24] DePsipherTM Kit. Trevigen, Inc. (2014) http://www.trevigen.com/item/3/14/94/621/DePsiphertrade_Kit/
[25] Snedecor, G.W. (1956) Statistical Methods. Iowa State University Press, Iowa.
[26] Gelmann, E.P. (1996) Tamoxifen Induction of Apoptosis in Estrogen Receptor-Negative Cancers: New Tricks for an Old Dog? Journal of the National Cancer Institute, 88, 224-226.
http://dx.doi.org/10.1093/jnci/88.5.224
[27] Mantena, S.K., Sharma, S.D. and Katiyar, S.K. (2006) Berberine Inhibits Growth, Induces G1 Arrest and Apoptosis in Human Epidermoid Carcinoma A431 Cells by Regulating Cdki-Cdk-Cyclin Cascade, Disruption of Mitochondrial Membrane Potential and Cleavage of Caspase 3 and PARP. Carcinogenesis, 27, 2018-2027. http://dx.doi.org/10.1093/carcin/bgl043
[28] Ly, J.D., Grubb, D.R. and Lawen, A. (2003) The Mitochondrial Membrane Potential (&Deltaψm) in Apoptosis; an Update. Apoptosis, 8, 115-128. http://dx.doi.org/10.1023/A:1022945107762
[29] Ellis, P.A., Saccani-Jott, G., Clarke, R., Johnston, S.R.D., Anderson, E., Howell, A., A’Hern, R., Saltar, J., Detre, S., Nicholson, R., Robertson, J., Smith, I.E. and Dowsett, M. (1997) Induction of Apoptosis by Tamoxifen and ICI 192780 in Primary Breast Cancer. International Journal of Cancer, 72, 608-613. http://dx.doi.org/10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7
[30] Sutherland, R., Hall, R. and Taylor, I. (1983) Cell Proliferation Kinetics of MCF-7 Human Mammary Carcinoma Cells in Culture and Effects of Tamoxifen on Exponentially Growing and Plateau-Phase Cells. Cancer Research, 43, 3998- 4006.
[31] Singh, B., Bhat, N. and Bhat, H. (2011) Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness. PLoS ONE, 6, 1-11. http://dx.doi.org/10.1371/journal.pone.0025125
[32] Guo, W., Shiina, I., Wang, Y., Umeda, E., Watanabe, C., Uetake, S., Ohashi, Y., Yamori, T. and Dan, S. (2013) Ridaifen-SB8, a Novel Tamoxifen Derivative, Induces Apoptosis via Reactive Oxygen Species-Dependent Signaling Pathway. Biochemical Pharmocology, 86, 1272-1284.
http://dx.doi.org/10.1016/j.bcp.2013.08.020
[33] Kallio, A., Zheng, A., Dahllund, J., Heiskanen, K. and Harkonen, P. (2005) Role of Mitochondria in Tamoxifen Induced Rapid Death of MCF-7 Breast Cancer Cells. Apoptosis, 10, 1395-1410.
http://dx.doi.org/10.1007/s10495-005-2137-z
[34] Hui, L., Zheng, Y., Yan, Y., Bargonetti, J. and Foster, D.A. (2006) Mutant p53 in MDA-MB-231 Breast Cancer Cells Is Stabilized by Elevated Phospholipase D Activity and Contributes to Survival Signals Generated by Phosopholipase D. Oncogene, 25, 7305-7310. http://dx.doi.org/10.1038/sj.onc.1209735
[35] Lin, V.C., Jin, R., Tan, P.H., Aw, S.E., Woon, C.T. and Bay, B.H. (2003) Progesterone Induces Cellular Differentiation in MDA-MB-231 Breast Cancer Cells Transfected with Progesterone Receptor Complementary DNA. American Journal of Pathology, 162, 1781-1787.
http://dx.doi.org/10.1016/S0002-9440(10)64313-1
[36] Al Amri, W.S., Balachandran, I., Thangirala, S., Coleman, A., El-Fawal, H.A.N. and Mousa, S.A. (2013) Differential Association between HER2/Neu and Angiogenesis in Breast Cancer. American Journal of Cancer Biology, 1, 1-15.
[37] Petinari, L., Kohn, L.K., de Carvalho, J.E. and Genari, S.C. (2004) Cytotoxicity of Tamoxifen in Normal and Tumoral cel Lines and Its Ability to Induce Cellular Transformation in Vitro. Cell Biology International, 28, 531-539. http://dx.doi.org/10.1016/j.cellbi.2004.04.008
[38] Shehata, M., van Amerongen, R., Zeeman, A.L., Giraddi, R.R. and Stingl, J. (2014) The Influence of Tamoxifen on Normalmouse Mammary Gland Homeostasis. Breast Cancer Research, 16, 411-421. http://dx.doi.org/10.1186/s13058-014-0411-0
[39] Pelicano, H., Zhang, W., Jinyun, L., Hammoudi, N., Dai, J., Rui-Hua, X., Lajos, P. and Huang, P. (2014) Mitochondrial Dysfunction in Some Triple-Negative Breast Cancer Cell Line: Role of mTOR Pathway and Therapeutic Potential. Breast Cancer Research, 434, 1-16.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.